HENLIUS (02696) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 28.2 billion, representing a 2.67% year-on-year increase. Gross profit reached RMB 21.99 billion, up 10.47% compared to the same period last year. Shareholders' attributable profit totaled RMB 390 million, marking a 0.99% year-on-year growth, with basic earnings per share of RMB 0.72.
According to the announcement, the Group recognized research and development expenses of approximately RMB 995 million during the period, an increase of about RMB 170 million from approximately RMB 826 million in the prior year period. This increase was primarily due to enhanced investment in innovative R&D projects to accelerate the Group's innovation transformation.
For the six months ended June 30, 2025, the Group's overseas products achieved sales revenue (including overseas product supply revenue and sales-based royalty income) of approximately RMB 40.6 million. Overseas product profits (including overseas product supply gross profit and sales-based royalty profits) achieved breakthrough growth of over 200% compared to the same period last year, primarily driven by the Group's international strategy and increased sales volume in the U.S. market, contributing to sustained improvement in international profitability levels.
As of August 22, 2025, the Group's six products (covering 25 indications) have been successfully approved and launched in China, the United States, Europe, Canada, Australia, Indonesia, Mexico, Bolivia, and other countries and regions. Among these, four products have been approved for launch in various overseas markets, covering nearly 60 countries and regions, benefiting over 850,000 patients globally.
Since the beginning of 2025, the Group's international expansion has achieved remarkable results. Hansizhuang® in combination with chemotherapy for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) was approved for launch in the European Union in February 2025, becoming the Group's second product approved in the EU and demonstrating full recognition of the Group's innovative products by major international markets.
In July 2025, the denosumab biosimilar HLX14 (recombinant anti-RANKL fully human monoclonal antibody injection) received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending approval for two Marketing Authorization Applications (MAAs) of different specifications, laying the foundation for HLX14's debut in broader overseas markets.